Jiaqi Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiaqi Feng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Baolin Hou
School of Mechanical Engineering, Nanjing University of Science and Technology, Nanjing, China
1 shared publication - Jia Li
Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication Jiafan Yao
1 shared publication- Liu Rong
Department of Critical Care Medicine, Shanghai Jiao Tong University School of Medicine Affiliated Shanghai General Hospital
1 shared publication - Na Li
Tianjin Key Laboratory of Civil Aircraft Airworthiness and Maintenance Civil Aviation University of China Tianjin China
1 shared publication Peng Xu
1 shared publication
Latest Publications
- 5 November 2024
- Published by Elsevier in Journal of Water Process Engineering
- Vol. 68, 106469
Catalytic degradation of tetracycline by nano-sized Cu3V2O8 ∙H2O activated periodate: Performance and mechanism
- 5 November 2024
- Published by Elsevier in Journal of Water Process Engineering
- Vol. 68, 106469
Catalytic degradation of tetracycline by nano-sized Cu3V2O8 ∙H2O activated periodate: Performance and mechanism
- Open Access
- 25 September 2020
- Published by Springer Nature in Research Square
Dynamic changes in serum IL-6, IL-8, and IL-10 are associated with the outcome of patients with severe COVID-19 in ICU
Background: Biomarkers that would help prognosticate outcomes and guide treatment of patients with severe coronavirus disease 2019 (COVID-19) are currently required. We aimed to investigate whether the dynamic variation of cytokines was associated with the survival of patients admitted to an intensive care unit (ICU).Methods: A retrospective study was performed on 40 patients with COVID-19 admitted to an ICU in Wuhan, China. Demographic, clinical, and laboratory variables were collected, and serum cytokines were kinetically assessed. A multivariable- adjusted generalized linear regression model was used to evaluate the differences in serum cytokine levels between survivor and non-survivors.Results: Among the 40 patients included, a significant positive correlation was found between multiple cytokines. Serum levels of IL-6, IL-10, and tumor necrosis factor alpha in non-survivors were consistently elevated compared to that of the survivors. Kinetic variations of IL-6, IL-8, and IL-10 were associated with a fatal outcome in severe patients with COVID-19, independent of sex, age, absolute lymphocyte count, direct bilirubin, hypertension, chronic obstructive pulmonary disease, and cancer.Conclusion: Dynamic changes in serum IL-6, IL-8, and IL-10 levels were associated with survival in ICU and could serve as a predictive biomarker in patients with severe COVID-19 to determine therapeutic options.
- 25 September 2020
- Published by Springer Nature in Research Square
Open AccessDynamic changes in serum IL-6, IL-8, and IL-10 are associated with the outcome of patients with severe COVID-19 in ICU
Background: Biomarkers that would help prognosticate outcomes and guide treatment of patients with severe coronavirus disease 2019 (COVID-19) are currently required. We aimed to investigate whether the dynamic variation of cytokines was associated with the survival of patients admitted to an intensive care unit (ICU).Methods: A retrospective study was performed on 40 patients with COVID-19 admitted to an ICU in Wuhan, China. Demographic, clinical, and laboratory variables were collected, and serum cytokines were kinetically assessed. A multivariable- adjusted generalized linear regression model was used to evaluate the differences in serum cytokine levels between survivor and non-survivors.Results: Among the 40 patients included, a significant positive correlation was found between multiple cytokines. Serum levels of IL-6, IL-10, and tumor necrosis factor alpha in non-survivors were consistently elevated compared to that of the survivors. Kinetic variations of IL-6, IL-8, and IL-10 were associated with a fatal outcome in severe patients with COVID-19, independent of sex, age, absolute lymphocyte count, direct bilirubin, hypertension, chronic obstructive pulmonary disease, and cancer.Conclusion: Dynamic changes in serum IL-6, IL-8, and IL-10 levels were associated with survival in ICU and could serve as a predictive biomarker in patients with severe COVID-19 to determine therapeutic options.